Financial Performance - Operating revenue for the first quarter reached CNY 29,472,938.03, a 17.42% increase year-on-year[11] - Net profit attributable to shareholders improved by 27.21% to a loss of CNY 3,239,570.36 compared to the same period last year[11] - Total operating revenue for Q1 2025 reached ¥29,472,938.03, a 17.5% increase from ¥25,100,709.69 in Q1 2024[38] - Operating profit for Q1 2025 was -¥3,237,906.01, an improvement from -¥4,450,874.50 in Q1 2024[38] - Net profit for Q1 2025 was -¥3,239,570.36, compared to -¥4,450,874.05 in Q1 2024, indicating a reduction in losses[39] - The total comprehensive loss for Q1 2025 was -¥3,239,570.36, compared to -¥4,450,874.05 in Q1 2024, reflecting an overall improvement[40] Cash Flow - Net cash flow from operating activities surged by 1,764.27% to CNY 12,612,429.32, primarily due to government subsidies received[11][12] - Cash inflow from operating activities totaled CNY 46,146,883.69, an increase from CNY 31,482,031.79 in the previous period, representing a growth of 46.6%[45] - Net cash flow from operating activities was CNY 12,612,429.32, a significant improvement compared to a negative cash flow of CNY -757,836.73 in the prior period[45] - The net increase in cash and cash equivalents was CNY 26,915,069.01, a substantial rise from CNY 1,336,650.48 in the previous period[46] - The ending balance of cash and cash equivalents reached CNY 52,589,902.75, significantly higher than CNY 21,137,550.78 at the end of the previous period[46] Assets and Liabilities - Total assets increased by 8.31% to CNY 426,072,602.07 compared to the end of the previous year[11] - The asset-liability ratio for the consolidated entity rose to 31.91%, compared to 25.43% at the end of the previous year[11] - Total liabilities reached CNY 135,946,360.22, up from CNY 100,018,121.68, indicating a growth of around 35.6%[33] - Current liabilities rose to CNY 95,574,466.26, compared to CNY 77,168,956.05, marking an increase of about 23.8%[32] - Non-current liabilities increased significantly to CNY 40,371,893.96 from CNY 22,849,165.63, reflecting an increase of approximately 76.5%[33] - Owner's equity decreased slightly to CNY 290,126,241.85 from CNY 293,365,812.21, a decline of about 1.0%[33] Shareholder Information - The total number of ordinary shareholders was reported at 5,936 as of the end of the reporting period[18] - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of total shares[20] - The total number of shares held by the top ten shareholders is 70,263,404, accounting for 63.09% of total shares[20] Inventory and Investments - Inventory rose to CNY 23,028,196.73 from CNY 19,147,617.40, representing an increase of about 20.0%[36] - Long-term equity investments increased to CNY 6,100,000.00 from CNY 3,600,000.00, marking an increase of about 69.4%[36] Expenses - Research and development expenses for Q1 2025 were ¥1,818,246.15, down from ¥2,226,327.07 in Q1 2024[41] - Sales expenses decreased to ¥2,877,982.94 in Q1 2025 from ¥3,213,744.05 in Q1 2024[41] - Management expenses for Q1 2025 were ¥4,092,979.85, a decrease from ¥4,935,422.02 in Q1 2024[41] Government Subsidies - The company received government subsidies totaling CNY 1,208,733.36, contributing to non-recurring gains[16]
大禹生物(871970) - 2025 Q1 - 季度财报